If you’re considering taking Belviq, you should understand all of the possible side effects and risks. Here’s a look at Cancers, Eye disorders, Increased Risk of Leukemia, and Liver Cancer. The FDA also warns healthcare professionals to stop prescribing the drug and to notify anyone they know who is taking it. The FDA has also published a warning for patients about Belviq’s risks.
Cancers linked to Belviq
Since the FDA approved Belviq in 2012, it has been linked to an increased risk of certain cancers, including breast and brain cancer. After reviewing the results of several studies, the agency recommended a recall of the drug. It is not clear exactly when the drug was recalled Belviq Side Effects or when the risks became known. Belviq has been linked to cancers in other people who have taken it, so the FDA is continuing to evaluate the risks of this drug.
In February 2020, the FDA requested a recall of Belviq XR. The company has not acknowledged the link, but they recommend that users stop using the drugs and find alternative methods of weight loss. It is important to note that the study sample size for Belviq was much smaller than that of Zantac, which is why the FDA did not require the drug makers to conduct studies on the drug’s risks for cancer.
Eye disorders linked to Belviq
Patients using the drug BELVIQ had more eye disorders than those taking the placebo, including dry eye, blurred vision, and visual impairment. It also caused cataracts and was linked to several ocular problems, including ocular sensitivities and conjunctivitis. Currently, the drug is approved by the Food and Drug Administration. However, it has been linked to serious eye disorders, including blindness and deafness.
In the FDA’s approval of Belviq in June 2012, researchers noted that the drug may cause certain types of cancer, including brain tumors and breast cancer. The company, Eisai, had to conduct a double-blind, placebo-controlled clinical trial before it was approved for human use. In that trial, approximately 12,000 people took Belviq for five years. The results were not promising. But, the FDA has a right to decide if a drug is safe and effective for its intended purpose.
Increased risk of leukemia
A new study reveals that patients taking Belviq XR face an increased risk of leukemia. In fact, the new study also found that patients taking Belviq have higher exposure to CYP 2D6 substrates. While there are currently no treatments to prevent leukemia, the study will help doctors and healthcare professionals decide whether to stop prescribing Belviq. However, in the meantime, the FDA has issued a warning to healthcare professionals and anyone using the drug about the risks.
Increased risk of liver cancer
FDA approval for Belviq was conditional upon the company conducting a double-blind, randomized clinical trial comparing placebos and the drug. FDA review of the trial data showed an increased risk of cancer in people taking the drug compared to placebos. Overall, one additional cancer case per 470 people took Belviq. However, the FDA also found no increased risk of cardiovascular disease. In addition, cancer rates were similar for people taking placebos as for those taking Belviq.
The FDA has recalled the drug Belviq after reviewing post-marketing reports and considering whether cancer is indeed a cause of death from the drug. Eisai said that it is working closely with the FDA to analyze the trial data but interpreted the results differently than the FDA. The FDA has deemed Belviq safe, but the company has yet to provide a statement about the risks of liver cancer associated with the drug.